+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.

Age: 60Years - 85YearsAll GendersPhase 3
128 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of zeleciment basivarsen DYNE-101 for treating myotonic dystrophy type 1 DM1. This phase 3 study includes participants diagnosed with DM1 confirmed by genetic testing and aims to assess the impact of DYNE-101 on physical function and disease symptoms. Participants are randomly assigned to receive either DYNE-101 or a matching placebo through intravenous infusion every 8 weeks during a 48-week placebo-controlled period. Following this, all participants enter a 24-week long-term extension where those initially on placebo switch to DYNE-101, and those on DYNE-101 continue the treatment. An Independent Data Monitoring Committee oversees safety and tolerability throughout the study. Participants undergo evaluations including the 5 Times Sit-To-Stand test as the primary outcome and various secondary measures such as hand opening time, muscle strength tests, walking speed, and patient and clinician global impressions. Blood samples are collected to monitor drug levels and immune responses. The total participation time may last up to approximately 80 weeks, including screening, treatment, and long-term follow-up assessments.

Age: 16Years +All GendersPhase 3
43 locations